Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, George S. Laszlo, PhD, Kathryn J. Newhall, PhD, Angus M. Sinclair, PhD, Stanley R. Frankel, MD, Roman Kischel, MD, Guang Chen, PhD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 266.

https://doi.org/10.1182/blood.V124.21.266.266

Published: 2014

Journal Articles

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall, Gary D. Means, Angus M. Sinclair, Roman Kischel, Stanley R. Frankel, Roland B. Walter

Blood (2014) 123 (4): 554–561.

https://doi.org/10.1182/blood-2013-09-527044

Published: 2014

Includes: Supplemental data

Journal Articles

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Thomas M Habermann, MD, Fangxin Hong, PhD, Vicki A. Morrison, MD, Shaker R. Dakhil, MD, James K. Weick, MD, Stanley R. Frankel, MD, Randy D. Gascoyne, MD, Richard I Fisher, MD, Bruce D. Cheson, MD, Edie A. Weller, PhD, Brad S. Kahl, M.D., Bruce A. Peterson, MD, Howard S Hochster, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 3705.

https://doi.org/10.1182/blood.V120.21.3705.3705

Published: 2012

Journal Articles

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Barry Turnbull, Parveen Wasi, Christos Emmanouilides, Stanley R. Frankel, Andrew Lister, Pierre Morel, Jeffrey Matous, Stephanie A. Gregory, Eva Kimby

Blood (2009) 113 (16): 3673–3678.

https://doi.org/10.1182/blood-2008-09-177329

Published: 2009

Journal Articles

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Steven Treon, MD, PhD, Andrew Branagan, Leukothea Ioakimidis, PhD, Jacob Soumerai, Christopher Patterson, MD, Parveen Wasi, MD, FRCP(C), Christos Emmanouilides, MD, PhD, Stanley R. Frankel, MD, T. Andrew Lister, MD, Pierre Morel, MD, Jeffrey Matous, MD, Stephanie A. Gregory, MD, Eva K. Kimby, MD, PhD

Blood (2008) 112 (11): 3057.

https://doi.org/10.1182/blood.V112.11.3057.3057

Published: 2008

Journal Articles

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Blood (2008) 111 (3): 1060–1066.

https://doi.org/10.1182/blood-2007-06-098061

Published: 2008

Includes: Supplemental data

Journal Articles

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Meir Wetzler, Ben L. Sanford, Joanne Kurtzberg, Divino DeOliveira, Stanley R. Frankel, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Richard A. Larson

Blood (2007) 109 (10): 4164–4167.

https://doi.org/10.1182/blood-2006-09-045351

Published: 2007

Includes: Supplemental data

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD

Blood (2006) 108 (11): 399.

https://doi.org/10.1182/blood.V108.11.399.399

Published: 2006

Journal Articles

Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.

Andrey Loboda, PhD, Valeria Fantin, PhD, Sophia Randolph, MD, PhD, Justin L. Ricker, MD, PhD, James S. Hardwick, PhD, Victoria M. Richon, PhD, Stanley R. Frankel, MD

Blood (2006) 108 (11): 4686.

https://doi.org/10.1182/blood.V108.11.4686.4686

Published: 2006

Journal Articles

High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.

Valeria R. Fantin, PhD, Andrey Loboda, PhD, Jennifer A. Roth, Cloud Paweletz, PhD, Sophia Randolph, MD, PhD, Jacqueline W. Pierce, PhD, Elizabeth A. Harrington, PhD, Ronald C. Hendrickson, PhD, John F. Reilly, PhD, Christopher Ware, Marshall E. Kadin, MD, Madeleine Duvic, MD, Stanley R. Frankel, MD, Victoria M. Richon, PhD

Blood (2006) 108 (11): 4679.

https://doi.org/10.1182/blood.V108.11.4679.4679

Published: 2006

Journal Articles

Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.

Andrey Loboda, PhD, Valeria R. Fantin, PhD, Carlos E. Bueso-Ramos, MD, PhD, Sophia Randolph, MD, PhD, James S. Hardwick, PhD, Justin L. Ricker, MD, PhD, Victoria M. Richon, PhD, Jean-Pierre Issa, MD, Hagop M. Kantarjian, MD, Stanley R. Frankel, MD, Guillermo Garcia-Manero, MD

Blood (2006) 108 (11): 2320.

https://doi.org/10.1182/blood.V108.11.2320.2320

Published: 2006

Journal Articles

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Chunlei Zhang, Parul Hazarika, Cecilia Kelly, Judy H. Chiao, John F. Reilly, Justin L. Ricker, Victoria M. Richon, Stanley R. Frankel

Blood (2006) 109 (1): 31–39.

https://doi.org/10.1182/blood-2006-06-025999

Published: 2006

Journal Articles

Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.

Howard S. Hochster, MD, Edie Weller, PhD, Randy D. Gascoyne, MD, Teresa S. Ryan, MD, Thomas M. Habermann, MD, Leo I. Gordon, MD, Stanley R. Frankel, MD, Sandra J. Horning, MD

Blood (2005) 106 (11): 349.

https://doi.org/10.1182/blood.V106.11.349.349

Published: 2005

Journal Articles

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Guillermo Garcia-Manero, MD, Hui Yang, MD, PhD, Blanca Sanchez-Gonzalez, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, Michael Keating, MD, Michael Andreeff, MD, Susan O’Brien, MD, Jorge Cortes, MD, William Wierda, MD, PhD, Stefan Faderl, MD, Charles Koller, MD, Jan Davis, RN, Gail Morris, RN, Jean-Pierre Issa, MD, Stanley R. Frankel, MD, Victoria Richon, PhD, Bernard Fine, PhD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 2801.

https://doi.org/10.1182/blood.V106.11.2801.2801

Published: 2005

Journal Articles

Effective Asparagine Depletion with Pegylated Asparaginase Results in Improved Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) — Cancer and Leukemia Group B Study 9511.

Meir Wetzler, MD, Ben L. Sanford, Kouros Owzar, Joanne Kurtzberg, MD, D. DeOliveira, MD, Stanley R. Frankel, MD, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 1825.

https://doi.org/10.1182/blood.V106.11.1825.1825

Published: 2005

Journal Articles

Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.

Steven P. Treon, Andrew Branagan, Parveen Wasi, Christos A. Emmanouilides, Stanley R. Frankel, Andrew Lister, Pierre Morel, Jeffrey Matous, Sari Heitner Enschede, Eva Kimby

Blood (2004) 104 (11): 753.

https://doi.org/10.1182/blood.V104.11.753.753

Published: 2004

Journal Articles

Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).

Joseph O. Moore, MD, Karen Seiter, MD, Jonathan E. Kolitz, MD, Wendy Stock, MD, Richard Yu, Stanley R. Frankel, MD

Blood (2004) 104 (11): 865.

https://doi.org/10.1182/blood.V104.11.865.865

Published: 2004

Journal Articles

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Blood (2003) 101 (2): 425–432.

https://doi.org/10.1182/blood-2002-06-1899

Published: 2003

NARROW

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.

High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.

Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Effective Asparagine Depletion with Pegylated Asparaginase Results in Improved Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) — Cancer and Leukemia Group B Study 9511.

Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.

Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only